Calcium News and Research

RSS

Calcium, the most abundant mineral in the body, is found in some foods, added to others, available as a dietary supplement, and present in some medicines (such as antacids). Calcium is required for muscle contraction, blood vessel expansion and contraction, secretion of hormones and enzymes, and transmitting impulses throughout the nervous system. The body strives to maintain constant concentrations of calcium in blood, muscle, and intercellular fluids, though less than <1% of total body calcium is needed to support these functions.

The remaining 99% of the body's calcium supply is stored in the bones and teeth where it supports their structure. Bone itself undergoes continuous remodeling, with constant resorption and deposition of calcium into new bone. The balance between bone resorption and deposition changes with age. Bone formation exceeds resorption in growing children, whereas in early and middle adulthood both processes are relatively equal. In aging adults, particularly among postmenopausal women, bone breakdown exceeds formation, resulting in bone loss that increases the risk of osteoporosis over time.

Whole-body-vibration does not effectively boost bone density

Whole-body-vibration, a popular exercise which uses a vibrating platform, is sometimes advertised as being able to boost bone density. However, a one-year-study on healthy postmenopausal women has shown that it has no such effect.

15 Nov 2011

CAS after prior revascularization safe, effective for carotid artery stenosis patients

A new study shows that carotid artery stenting (CAS) following prior same-side carotid artery revascularization is safe, effective and results in lower incidences of in-hospital death, stroke and heart attack compared to first-time CAS for carotid artery stenosis.

15 Nov 2011

Teeth whitening tips

Both women and men go to great lengths, ranging from at-home-kits to cosmetic bleaching, to make their smile full of pearly whites. But what if there were more natural ways to keep teeth white instead of experiencing the repercussions of using these chemicals?

14 Nov 2011

Researchers identify how to design drugs to target specific brain areas

The future of drug design lies in developing therapies that can target specific cellular processes without causing adverse reactions in other areas of the nervous system. Scientists at the Universities of Bristol and Li-ge in Belgium have discovered how to design drugs to target specific areas of the brain.

11 Nov 2011

Obese premenopausal women may benefit from dairy food consumption

A recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM) found that consumption of dairy foods and higher protein resulted in improvements in markers of bone formation and reductions in markers of bone degradation in overweight and obese young women over 16 weeks of diet- and exercise-induced weight loss.

10 Nov 2011

Treatments can help most HCM patients

Most of the 600,000 Americans with hypertrophic cardiomyopathy (HCM) -- a genetic heart muscle disease -- can live normal life spans, according to the first science-based guideline for diagnosing and treating this disorder.

9 Nov 2011

Bristol-Myers Squibb receives FDA approval for Erbitux to treat head and neck cancer

The U.S. Food and Drug Administration today approved Erbitux (cetuximab) for use with chemotherapy to treat patients with late-stage (metastatic) head and neck cancer.

8 Nov 2011

Gilead, CRF commence ranolazine Phase 3 clinical trial for chronic stable angina in post-PCI setting

Gilead Sciences, Inc. and the Cardiovascular Research Foundation (CRF) today announced the initiation of RIVER-PCI (Ranolazine for Incomplete VEssel Revascularization post-PCI), a Phase 3 clinical trial evaluating the utility of ranolazine to prevent major adverse cardiovascular events (MACE) in patients with a history of chronic angina who have incomplete revascularization following percutaneous coronary intervention (PCI).

7 Nov 2011

DuoCort Pharma granted marketing authorization for adrenal insufficiency drug, Plenadren in Europe

The Swedish specialty pharma company, DuoCort Pharma, announced today that the European Commission has granted a European Marketing Authorisation for Plenadren (hydrocortisone, modified release tablet), an orphan drug for treatment of adrenal insufficiency in adults, bringing these patients their first pharmaceutical innovation in over 50 years.

7 Nov 2011

Positive top-line results from NPSP558 Phase 3 study on hypoparathyroidism

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today announced positive top-line results from REPLACE, a Phase 3 registration study of NPSP558, the company's bioengineered replica of human parathyroid hormone (rhPTH 1-84), in adult hypoparathyroidism patients.

7 Nov 2011

Vitamin D supplementation benefits people with lupus

The first study to report the effects vitamin D has on the immune system of people with lupus was reported this week a the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

Cabot's 5-Day Menu Planner seeks to refocus eating habits to balance nutrition

November is American Diabetes Month, and the American Diabetes Association has released some startling facts on just how prevalent the disease has become in the United States.

5 Nov 2011

Baxter launches NUMETA emulsion for infusion in Europe

Baxter International Inc. announced today the European launch of NUMETA (emulsion for infusion).

From Baxter International Inc. 4 Nov 2011

Edwards Lifescience receives FDA approval for Sapien Transcatheter Heart Valve

The U.S. Food and Drug Administration today approved the first artificial heart valve that can replace an aortic heart valve damaged by senile aortic valve stenosis without open-heart surgery.

3 Nov 2011

Many spinal fusion surgery patients have low levels of vitamin D

A new study indicates that many patients undergoing spine surgery have low levels of vitamin D, which may delay their recovery. In a study of 313 patients undergoing spinal fusion surgery, orthopaedic surgeons at Washington University School of Medicine in St. Louis found that more than half had inadequate levels of vitamin D, including one-fourth who were more severely deficient.

3 Nov 2011

Researchers identify small-molecule drug candidates for many metabolic conditions

A new discovery by Californian scientists may lead to a pharmaceutical breakthrough for a wide range of illnesses that involve the hydration of cells that line the inner surfaces of our body's organs and tissues. In a new report appearing in the FASEB Journal, the researchers describe how they used high-throughput screening to identify small-molecule drug candidates which help cells bypass defective channels that normally move salt and water through cell membranes.

2 Nov 2011

Vitamin D does not confer benefits against mortality in postmenopausal women

Doctors agree that vitamin D promotes bone health, but a belief that it can also prevent cancer, cardiovascular disease and other causes of death has been a major health controversy. Consistent with advice issued last fall by the Institute of Medicine, a new study finds that vitamin D did not confer benefits against mortality in postmenopausal women after controlling for key health factors such as abdominal obesity.

2 Nov 2011

SmartTots sets agenda for research on anesthetic safety in children

A special section of the November issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS), presents new research, updates, and commentaries about possible toxic effects of anesthetics and sedatives in infants and young children. The IARS is a key partner in the SmartTots initiative, dedicated to finding scientific answers to these urgent public health concerns.

2 Nov 2011

Heat, extreme exercise or febrile illness may also trigger MH

Malignant hyperthermia (MH) is a potentially life-threatening inherited disorder of muscle. Patients who are at risk for MH usually have no outward signs of muscle problems. However, when exposed to certain commonly used general anesthetics they may develop very high body temperature, increased heart rate and muscle breakdown. If not recognized and treated promptly MH may be fatal.

1 Nov 2011

NPS announces new data from GATTEX Phase 3 study on short bowel syndrome

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced new data from STEPS 2, a long-term open-label study, showing that GATTEX (teduglutide) was associated with achieving and maintaining clinically meaningful reductions in parenteral nutrition (PN) and intravenous (IV) fluid volume in adult subjects with short bowel syndrome.

1 Nov 2011